期刊
CANCER
卷 113, 期 7, 页码 1666-1675出版社
WILEY
DOI: 10.1002/cncr.23772
关键词
breast cancer; peptide; vaccine; E75; dosing
类别
资金
- United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences
- Department of Clinical Investigation at Walter Reed Army Medical Center.
BACKGROUND. E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with graulocyte-macrophage-colony-stimulating factor (GM-CSF) in disease-free lymph node-positive (NP) and lymph node-negative (NN) breast cancer (BCa) patients. The optimal biologic dose (OBD) was determined based on toxicity and immunologic response. METHODS. Patients were vaccinated over 6 months (3, 4, or 6 times) with different doses of E75 plus GM-CSF. Toxicities were graded per National Cancer Institute Common Terminology Criteria. GM-CSF vas reduced for significant toxicity Immunologic response was measured by delayed type hypersensitivity test (DTH), and E75-specific CD8(+) T-cells were quantified with human leukocyte antigen-A2:immunoglobulin G diner and flow cytometry. RESULTS. Ninety-nine patients (48 NP and 51 NN) were vaccinated in 7 dose groups. The OBD was 1000 mu g E75 plus 250 mu g GM-CSF monthly x 6. The optimal dose group (ODG, n = 29) experienced similar toxicities to the suboptimal dose group (SDG, n = 70), which was comprised of the remaining 6 groups. The ODG demonstrated a trend toward an increase in the average postvaccine dimer (0.87 +/- 0.10% vs 0.67 +/- 0.05%; P =.07), a significantly larger DTH response (21.5 +/- 2.5 mm vs 11.3 +/- 1.3 mm; P =.0002), and a trend toward decreased recurrences (3.4% vs 12.9%; P =.27). Compared with the SDG, the ODG had larger tumors (percentage >= T2: 55% vs 23%; P =.004), more positive nodes (percentage NP: 76% vs 37%; P =.001), and higher grade tumors (percentage grade 3: 52% vs 30%; P =.07), but a shorter median follow-up time (20 months vs 32 months; P <.001). CONCLUSIONS. Compared with suboptimally dosed patients, the optimally dosed E75 vaccine in disease-free BCa patients had similar toxicity but enhanced HER-2/neu-specific immunity that may lead to decreased recurrences with additional follow-up.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据